Abstract
Background/Aims: Leukocytes, such as lymphocytes and macrophages, predominantly express delayed rectifier K+ channels (Kv1.3) in their plasma membranes. In our previous study, the overexpression of these channels in leukocytes was strongly associated with their proliferation in kidneys and the progression of renal fibrosis in advanced-stage chronic renal failure (CRF). Since benidipine, a long-acting 1,4-dihydropyridine Ca2+ channel blocker, is also highly potent as a Kv1.3 channel inhibitor, it could exert therapeutic efficacy in advanced CRF. Methods: Male Sprague-Dawley rats that underwent 5/6 nephrectomy followed by a 14-week recovery period were used as the model of advanced CRF. Benidipine hydrochloride (5 mg/kg) was started at 8 weeks after nephrectomy and orally administered daily for 6 weeks. The histopathological features of the kidneys were examined in vehicle-treated and benidipine-treated CRF rat kidneys. Cellular proliferation of leukocytes and the cortical expression of proinflammatory cytokines were also examined. Results: In CRF rat kidneys, Kv1.3 channels began to be overexpressed in leukocytes as early as 8 weeks after nephrectomy. In the cortical interstitium of benidipine-treated CRF rat kidneys, both immunohistochemistry and real-time PCR demonstrated decreased expression of fibrotic markers. Benidipine treatment significantly reduced the number of proliferating leukocytes within the cortical interstitium and decreased the expression of cell cycle markers and proinflammatory cytokines. Conclusion: This study demonstrated for the first time that benidipine slowed the progression of renal fibrosis in rat kidneys with advanced CRF. Kv1.3 channels overexpressed in leukocytes were thought to be the most likely therapeutic targets of benidipine in decreasing the number of proliferating leukocytes and repressing the production of inflammatory cytokines.
References
1.
Bohle A, Strutz F, Müller GA: On the pathogenesis of chronic renal failure in primary glomerulopathies: a view from the interstitium. Exp Nephrol 1994;2:205-210.
[PubMed]
2.
Michimata M, Kazama I, Mizukami K, Araki T, Nakamura Y, Suzuki M, et al: Urinary concentration defect and limited expression of sodium cotransporter, rBSC1, in a rat model of chronic renal failure. Nephron Physiol 2003;93:34-41.
[PubMed]
3.
Kumano K, Kogure K, Tanaka T, Sakai T: A new method of inducing experimental chronic renal failure by cryosurgery. Kidney Int 1986;30:433-436.
[PubMed]
4.
Hayashi K, Homma K, Wakino S, Tokuyama H, Sugano N, Saruta T, et al: T-type Ca channel blockade as a determinant of kidney protection. Keio J Med 2010;59:84-95.
[PubMed]
5.
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857-1863.
[PubMed]
6.
Lewis RS, Cahalan MD: Potassium and calcium channels in lymphocytes. Annu Rev Immunol 1995;13:623-653.
[PubMed]
7.
Hu L, Pennington M, Jiang Q, Whartenby KA, Calabresi PA: Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes. J Immunol 2007;179:4563-4570.
[PubMed]
8.
Kazama I, Maruyama Y, Endo Y, Toyama H, Ejima Y, Matsubara M, et al: Overexpression of delayed rectifier K(+) channels promotes in situ proliferation of leukocytes in rat kidneys with advanced chronic renal failure. Int J Nephrol 2012;2012:581581.
[PubMed]
9.
Grgic I, Kiss E, Kaistha BP, Busch C, Kloss M, Sautter J, et al: Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci USA 2009;106:14518-14523.
[PubMed]
10.
Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981;241:F85-F93.
[PubMed]
11.
Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307:652-659.
[PubMed]
12.
Karasawa A, Kubo K, Shuto K, Oka T, Nakamizo N: Antihypertensive effects of the new calcium antagonist benidipine hydrochloride in rats. Arzneimittelforschung 1988;38:1684-1690.
[PubMed]
13.
Kazama I, Maruyama Y, Matsubara M: Benidipine persistently inhibits delayed rectifier K(+)-channel currents in murine thymocytes. Immunopharmacol Immunotoxicol 2013;35:28-33.
[PubMed]
14.
Kazama I, Endo Y, Toyama H, Ejima Y, Kurosawa S, Murata Y, et al: Compensatory thrombopoietin production from the liver and bone marrow stimulates thrombopoiesis of living rat megakaryocytes in chronic renal failure. Nephron Extra 2011;1:147-156.
[PubMed]
15.
Nakamura T, Obata JE, Onitsuka M, Shimada Y, Yoshida Y, Kawachi H, et al: Benidipine, a long-acting calcium-channel blocker, prevents the progression to end-stage renal failure in a rat mesangioproliferative glomerulonephritis. Nephron 2000;86:315-326.
[PubMed]
16.
Kazama I, Mahoney Z, Miner JH, Graf D, Economides AN, Kreidberg JA: Podocyte-derived BMP7 is critical for nephron development. J Am Soc Nephrol 2008;19:2181-2191.
[PubMed]
17.
Dubrulle MP, Terzi F, Gubler MC, Kleinknecht C, Schaeverbeke M: Changes in thickness and anionic sites of the glomerular basement membrane after subtotal nephrectomy in the rat. Am J Pathol 1992;141:1481-1489.
[PubMed]
18.
Michelacci YM, Cadaval RA, Rovigatti RM, Kohlman O: Renal and urinary glycosaminoglycans in an experimental model of chronic renal failure in rats. Exp Nephrol 2001;9:40-48.
[PubMed]
19.
Jang SH, Choi SY, Ryu PD, Lee SY: Anti-proliferative effect of Kv1.3 blockers in A549 human lung adenocarcinoma in vitro and in vivo. Eur J Pharmacol 2011;651:26-32.
[PubMed]
20.
Kalman K, Pennington MW, Lanigan MD, Nguyen A, Rauer H, Mahnir V, et al: ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J Biol Chem 1998;273:32697-32707.
[PubMed]
21.
Jernigan SM, Eddy AA: Experimental insights into the mechanisms of tubulointerstitial scarring; in El Nahas AMAS, Harris KPG (eds): Mechanisms and Management of Progressive Renal Failure. London, Oxford University Press, 2000, pp 104-145.
22.
Furukawa T, Nukada T, Miura R, Ooga K, Honda M, Watanabe S, et al: Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (alpha1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol 2005;45:241-246.
[PubMed]
23.
Yamamoto E, Kataoka K, Dong YF, Nakamura T, Fukuda M, Nako H, et al: Benidipine, a dihydropyridine L-type/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive rats. J Hypertens 2010;28:1321-1329.
[PubMed]
24.
Gao H, Wang F, Wang W, Makarewich CA, Zhang H, Kubo H, et al: Ca(2+) influx through L-type Ca(2+) channels and transient receptor potential channels activates pathological hypertrophy signaling. J Mol Cell Cardiol 2012;53:657-667.
[PubMed]
25.
Sugano N, Wakino S, Kanda T, Tatematsu S, Homma K, Yoshioka K, et al: T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int 2008;73:826-834.
[PubMed]
26.
Amann K, Nichols C, Tornig J, Schwarz U, Zeier M, Mall G, et al: Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996;11:1003-1011.
[PubMed]
27.
Oliveria SA, Chen RS, McCarthy BD, Davis CC, Hill MN: Hypertension knowledge, awareness, and attitudes in a hypertensive population. J Gen Intern Med 2005;20:219-225.
[PubMed]
28.
Toto RD: Management of hypertensive chronic kidney disease: role of calcium channel blockers. J Clin Hypertens (Greenwich) 2005;7:15-20.
[PubMed]
29.
Katki KA, Supowit SC, DiPette DJ: Substance P in subtotal nephrectomy-salt hypertension. Hypertension 2002;39:389-393.
[PubMed]
30.
Yamamoto M, Gotoh Y, Imaizumi Y, Watanabe M: Mechanisms of long-lasting effects of benidipine on Ca current in guinea-pig ventricular cells. Br J Pharmacol 1990;100:669-676.
[PubMed]
31.
Hayashi K, Wakino S, Homma K, Sugano N, Saruta T: Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J Pharmacol Sci 2005;99:221-227.
[PubMed]
32.
Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Sugaya T, et al: Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. Am J Med Sci 2010;339:157-163.
[PubMed]
33.
Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, et al: Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 2010;77:550-556.
[PubMed]
34.
Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192:565-570.
[PubMed]
35.
Kazama I, Maruyama Y: Differential effects of clarithromycin and azithromycin on delayed rectifier K(+)-channel currents in murine thymocytes. Pharm Biol 2013;51:760-765.
[PubMed]
36.
Kazama I, Maruyama Y, Murata Y, Sano M: Voltage-dependent biphasic effects of chloroquine on delayed rectifier K(+)-channel currents in murine thymocytes. J Physiol Sci 2012;62:267-274.
[PubMed]
37.
Lewis RJ, Garcia ML: Therapeutic potential of venom peptides. Nat Rev Drug Discov 2003;2:790-802.
[PubMed]
38.
Judge SI, Lee JM, Bever CT Jr, Hoffman PM: Voltage-gated potassium channels in multiple sclerosis: overview and new implications for treatment of central nervous system inflammation and degeneration. J Rehabil Res Dev 2006;43:111-122.
[PubMed]
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.
